Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rineterkib in advanced solid tumors with MAPK pathway alterations
NCT02711345Phase 1Terminated
- Sponsor
- Novartis
- Start
- Apr 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of rineterkib in solid tumor, ovarian cancer, non-small cell lung cancer (NSCLC) and 1 more (5 arms), sponsored by Novartis. Primary endpoints: Adverse Events and Serious Adverse Events up to 2.8 years, Dose Limiting Toxicities up to 2.8 years and 3 more. Started Apr 2016; status: terminated.
02
Drugs
rineterkib
03
Conditions
solid tumorovarian cancernon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT02711345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711345.